• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing
The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine
Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments
Ibogaine's Momentum Is Real. So Is the Safety Gap Nobody's Solving.
Psychedelic Medicine Is Having an Identity Crisis — And That's a Good Thing
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won't Get You High
FDA's New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.
The Psychedelic Sector Has Grown Up. Wall Street Just Hasn't Fully Realized It Yet
Medical Psilocybin Act
PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field
Shop

New Study Shows Microdoses Reduce Compulsive Behavior (in rats)

Jason Najum by Jason Najum
October 11, 2023
in Science
Reading Time: 1 min read
A A
mushroom rats

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

 

Published in Molecular Psychiatry, this new study gives some observational data to support people’s anecdotal reports on the benefits of microdosing.

Researchers gave a microdose-like regimen to rats, using repeated low doses of psilocybin. The rodents tolerated the repeated low doses of psilocybin well and did not manifest signs of anxiety, altered locomotor activity, or anhedonia (loss of ability to feel pleasure, common symptom of depressive disorders).

According to the study:

[bsa_pro_ad_space id=2]
ADVERTISEMENT

“…the repeated low doses of psilocybin imparted resilience against the stress of multiple subcutaneous injections, and reduced the frequency of self-grooming, a proxy for human compulsive actions.”

Order Lasix By Mail

Compulsive self-grooming — does sound like something I might do when stressed. More microdoses please.

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Read more here.

 

Image1
[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: Microdosing
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
cybin deal

Cybin Shareholders Approve Acquisition of Small Pharma

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.